Stockholders Approve Incentive Plan Authorizing 14.75% Potential Dilution
RARE sits 33% above its 52-week low of $18.29 on light trading volume (0.2× avg).
Summary
Ultragenyx Pharmaceutical Inc. stockholders approved an amended incentive plan, authorizing the issuance of up to 14.5 million new shares, which could lead to a potential dilution of approximately 14.75% of outstanding shares.
Key Events · Financing and Capital Events · RARE
-
Incentive Plan Approved
Stockholders approved the Third Amended and Restated 2023 Incentive Plan at the Annual Meeting on May 14, 2026.
-
Significant Share Authorization
The approved plan authorizes the issuance of up to 14,500,000 new shares for equity awards.
-
Potential Dilution
If all authorized shares were issued, dilution would be approximately 14.75% based on the 98,317,221 shares outstanding as of March 23, 2026.
-
Routine Annual Meeting Outcomes
Other proposals, including the election of three Class I directors, ratification of Ernst & Young LLP as the independent accounting firm, and an advisory vote on executive compensation, were also approved.
Analysis · RARE · Life Sciences
The approval of the Third Amended and Restated 2023 Incentive Plan by stockholders authorizes Ultragenyx to issue up to 14.5 million new shares for equity awards. This represents a substantial potential dilution of approximately 14.75% of the company's currently outstanding shares. While incentive plans are standard for attracting and retaining talent, the magnitude of this authorization creates a significant overhang for existing shareholders, as these shares will be issued over time, increasing the total share count.
At the time of this filing, RARE was trading at $24.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $18.29 to $42.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.